The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas

Cancer Investigation

Volumn 30, Issue 8, 2012, Pages 571-576

  Balmanoukian, Ani ^a   Ye, Xiaobu ^b   Herman, Joseph ^b   Laheru, Daniel ^b   Grossman, Stuart A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chemotherapy; Immunosuppression; Lymphopenia; Pancreatic cancer; Radiation

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; POSTOPERATIVE CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHOCYTE COUNT; LYMPHOPENIA; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT;

EID: 84866867291     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.700987     Document Type: Article

References (33)

1. Ehrlich P. Über den jetzigen stand der karzinomforschung. Ned Tijdschr Geneeskd 1909;5:273-290.
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immuno surveillance to tumor escape. Nat Immunol 2002;3:991-998.
3. Prestwich RJ, Errington F, Hatfield P, Merrick AE, Ilett EJ, Selby PJ, MelcherAA.The immune system-is it relevant to cancer development, progression and treatment? Clin Oncol (R Coll Radiol) 2008;20:101-112.
4. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest 2007;117:1137-1146.
5. Dodson LF, Hawkins WG, Goedegebuure P. Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy 2011;3:517-537.
6. Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S, for the NABTT CNS Consortium. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 2011;15:5473-5480.
7. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, Campbell KA, Wolfgang CL, Asrari F, Donehower R, Hidalgo M, Diaz LA, Jr, Yeo C, Cameron JL, Schulick RD, Abrams R. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008;26:3503-3510.
8. Rothenberg ML, Benedetti JK, Macdonald JS, Seay TE, Neubauer MA, George CS, Tanaka MS, Jr, Giguere JK, Pruitt BT, Abbruzzese JL. Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. Ann Oncol 2002;13:1576-1582.
9. Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J, Lawrence TS, McGinn CJ. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 2003;7:766-772.
10. Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, Navaglia F, Zambon CF, Pasquali C, Venza E, Pedrazzoli S, Plebani M. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 2006;32:22-28.
11. An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ, He YJ, Xu RH, Jiang WQ. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 2010;15:516-522.
12. Stocken DD, Hassan AB, Altman DG, Billingham LJ, Bramhall SR, Johnson PJ, Freemantle N. Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer 2008;99:883-893.
13. Ueda M, Endo I, Nakashima M, Minami Y, Takeda K, Matsuo K, Nagano Y, Tanaka K, Ichikawa Y, Togo S, Kunisaki C, Shimada H. Prognostic factors after resection of pancreatic cancer. World J Surg 2009;33:104-110.
14. Kaplan EL, Meir P. Nonparametric estimation from incomplete observations. J Amer Statist Assn 1958;53:457-481.
15. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41.
16. Clark EJ, Connor S, Taylor MA, Madhavan KK, Garden OJ, Parks RW. Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB (Oxford) 2007;9:456-460.
17. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, Williams L, Foster T, Sepkowitz KA, Chapman PB. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004;22:610-616.
18. Kleinberg L, Grossman SA, Piantadosi S, Zeltzman M, Wharam M. The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma. Int J Radiat Oncol Biol Phys 1999;44:535-543.
19. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.
20. Yeo C, Abrams RA, Grochow LB, Sohn TA, Ord SE, Hruban RH, Zahurak ML, Dooley WC, Coleman J, Sauter PK, Pitt HA, Lillemoe KD, Cameron JL. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival: a prospective, single-institution experience. Ann Surg 1997;225:621-633; discussion 633-6.
21. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, deWit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-782; discussion 782-784.
22. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, FalconiM, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW; European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-1585.
23. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210.
24. Meyer KK. Radiation-induced lymphocyte-immune deficiency: a factor in the increased visceral metastases and decreased hormonal responsiveness of breast cancer. Arch Surg 1970;101: 114-121.
25. Hoppe RT, Fuks ZY, Strober S, Kaplan HS. The long term effects of radiation of T and B lymphocytes in the peripheral blood after regional irradiation. Cancer 1977;40:2071-2078.
26. Idestrom K, Petrini B, Blomgren H, Wasserman J, Wallgren A, Baral E. Changes of the peripheral lymphocyte population following radiation therapy to extended and limited fields. Int J Radiat Oncol Biol Phys 1979;5:1761-1766.
27. Louagie H, Van Eijkeren M, Philippe J, Thierens H, de Ridder L. Changes in peripheral blood lymphocyte subsets in patients undergoing radiotherapy. Int J Radiat Biol 1999;75:767-771.
28. Lissoni P, Meregalli S, Bonetto E, Mancuso M, Brivio F, Colciago M, Gardani G. Radiotherapy-induced lymphocytopenia: changes in total lymphocyte count and in lymphocyte subpopulations under pelvic irradiation in gynecologic neoplasms. J Biol Regul Homeost Agents 2005;19:153-158.
29. Standish LJ, Torkelson C, Hamill FA, Yim D, Hill-Force A, Fitzpatrick A, Olsen M, Schildt S, Sweet E, Wenner CA, Martzen MR. Immune defects in breast cancer patients after radiotherapy. J Soc Integr Oncol 2008;6:110-121.
30. Lissoni P, Rovelli F, Brivio F, Fumagalli L, Brera G. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients. In Vivo 2008;22:397-400.
31. United Nations Scientific Committee on the Effects of Atomic Radiation -UNSCEAR 2006 (ed.) Effects of ionizing radiation on the immune system. In United Nations, 2nd volume, Appendix D. Vienna, Austria: United Nations Office; 81-195.
32. Kitayama J, Yasuda K, Kawai K, Sunami E, Nagawa H. Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer 2011;11:64.
33. Hughes MA, ParisiM, Grossman S, Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys 2005;62:1423-1426.